Last reviewed · How we verify

abciximab bolus only regimen — Competitive Intelligence Brief

abciximab bolus only regimen (abciximab bolus only regimen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycoprotein IIb/IIIa inhibitor. Area: Cardiovascular.

marketed Glycoprotein IIb/IIIa inhibitor Glycoprotein IIb/IIIa integrin receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

abciximab bolus only regimen (abciximab bolus only regimen) — Università degli Studi di Ferrara. Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
abciximab bolus only regimen TARGET abciximab bolus only regimen Università degli Studi di Ferrara marketed Glycoprotein IIb/IIIa inhibitor Glycoprotein IIb/IIIa integrin receptor
abciximab intracoronary abciximab intracoronary University of Leipzig phase 3 Glycoprotein IIb/IIIa inhibitor Glycoprotein IIb/IIIa integrin receptor
Abciximab; reteplase; abciximab placebo; abciximab Abciximab; reteplase; abciximab placebo; abciximab Centocor, Inc. phase 3 Glycoprotein IIb/IIIa inhibitor Glycoprotein IIb/IIIa integrin receptor
Glycoprotein IIb/IIIa inhibitors Glycoprotein IIb/IIIa inhibitors University of Luebeck marketed Glycoprotein IIb/IIIa inhibitor Glycoprotein IIb/IIIa receptor
Abciximab + UFH Abciximab + UFH Deutsches Herzzentrum Muenchen marketed Glycoprotein IIb/IIIa inhibitor (in combination with anticoagulant) Platelet glycoprotein IIb/IIIa receptor
clopidogrel/abciximab clopidogrel/abciximab I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio marketed Dual antiplatelet agent (P2Y12 inhibitor + glycoprotein IIb/IIIa inhibitor) P2Y12 receptor (clopidogrel); glycoprotein IIb/IIIa integrin (abciximab)
Bivalirudin with and without eptifibatide Bivalirudin with and without eptifibatide LifeBridge Health marketed Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide) Thrombin (Factor IIa) and Glycoprotein IIb/IIIa receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycoprotein IIb/IIIa inhibitor class)

  1. Beijing Tiantan Hospital · 1 drug in this class
  2. Centocor, Inc. · 1 drug in this class
  3. General Hospital of Shenyang Military Region · 1 drug in this class
  4. Ministry of Science and Technology of the People´s Republic of China · 1 drug in this class
  5. Organon and Co · 1 drug in this class
  6. Ottawa Heart Institute Research Corporation · 1 drug in this class
  7. University of Leipzig · 1 drug in this class
  8. University of Luebeck · 1 drug in this class
  9. Università degli Studi di Ferrara · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). abciximab bolus only regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/abciximab-bolus-only-regimen. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: